18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma

Oncologist. 2008 Jun;13(6):734-5; author reply 736-7. doi: 10.1634/theoncologist.2008-0063.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Hepatocellular / diagnostic imaging*
  • Carcinoma, Hepatocellular / drug therapy
  • Fluorodeoxyglucose F18*
  • Humans
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / drug therapy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Positron-Emission Tomography / methods*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridines / therapeutic use*
  • Radiopharmaceuticals*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Sorafenib

Substances

  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Niacinamide
  • Sorafenib
  • Receptors, Vascular Endothelial Growth Factor